Y

YSP Southeast Asia Holding Bhd
KLSE:YSPSAH

Watchlist Manager
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
Watchlist
Price: 2.2 MYR -1.79%
Market Cap: 312m MYR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one YSPSAH stock under the Base Case scenario is 2.36 MYR. Compared to the current market price of 2.2 MYR, YSP Southeast Asia Holding Bhd is Undervalued by 7%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

YSPSAH Relative Value
Base Case
2.36 MYR
Undervaluation 7%
Relative Value
Price
Y
Worst Case
Base Case
Best Case

Valuation Multiples

0.8
P/S
P/S
Price to Sales
0.8
vs History
93
vs Industry
73
Median 3Y
1
Median 5Y
1
Industry
2.4
More Details
11.7
P/E
P/E
Price to Earnings
11.7
vs History
46
vs Industry
37
Median 3Y
10.4
Median 5Y
11.4
Industry
20.5
More Details
6.3
P/OCF
P/OCF
Price to OCF
6.3
vs History
68
vs Industry
45
Median 3Y
7.3
Median 5Y
8.1
Industry
15.6
More Details
12.1
P/FCFE
P/FCFE
Price to FCFE
12.1
vs History
63
vs Industry
28
Median 3Y
13.7
Median 5Y
15.3
Industry
23.1
More Details
0.8
P/B
P/B
Price to Book Value
0.8
vs History
87
vs Industry
67
Median 3Y
0.9
Median 5Y
0.9
Industry
2
More Details
0.6
EV/S
EV/S
Enterprise Value to Sales
0.6
vs History
88
vs Industry
84
Median 3Y
0.7
Median 5Y
0.7
Industry
2.5
More Details
1.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
1.4
vs History
88
vs Industry
79
Median 3Y
1.6
Median 5Y
1.7
Industry
4.9
More Details
5.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
5.4
vs History
53
vs Industry
46
Median 3Y
5
Median 5Y
5.5
Industry
12.3
More Details
5.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
5.4
vs History
58
vs Industry
46
Median 3Y
5
Median 5Y
5.7
Industry
15.5
More Details
4.3
EV/OCF
EV/OCF
Enterprise Value to OCF
4.3
vs History
74
vs Industry
50
Median 3Y
5
Median 5Y
5.8
Industry
14.1
More Details
5.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
5.2
vs History
57
vs Industry
37
Median 3Y
5.4
Median 5Y
5.5
Industry
17.5
More Details
0.6
EV/IC
EV/IC
Enterprise Value to IC
0.6
vs History
87
vs Industry
73
Median 3Y
0.7
Median 5Y
0.7
Industry
1.8
More Details

Multiples Across Competitors

YSPSAH Competitors Multiples
YSP Southeast Asia Holding Bhd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
MY
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
312.1m MYR 0.8 11.7 5.4 5.4
US
Eli Lilly and Co
NYSE:LLY
716.1B USD 14.6 64.5 34.7 37.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
370.8B USD 4.2 17 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.8 19.4 12.8 14.6
CH
Roche Holding AG
SIX:ROG
208.3B CHF 3.4 25.2 9.5 11.1
CH
Novartis AG
SIX:NOVN
179.6B CHF 4 16.6 9.8 13.1
UK
AstraZeneca PLC
LSE:AZN
159.3B GBP 3.8 27 130.3 196.5
US
Merck & Co Inc
NYSE:MRK
202.4B USD 3.2 11.6 8.6 10.5
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
131.3B USD 2.1 16.7 7.2 10.2
P/E Multiple
Earnings Growth PEG
MY
Y
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
Average P/E: 23.3
11.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
64.5
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.4
18%
1.1
CH
Roche Holding AG
SIX:ROG
25.2
32%
0.8
CH
Novartis AG
SIX:NOVN
16.6
17%
1
UK
AstraZeneca PLC
LSE:AZN
27
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.6
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.7
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
MY
Y
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
Average EV/EBITDA: 394.4
5.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.7
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.5
6%
1.6
CH
Novartis AG
SIX:NOVN
9.8
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.3
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.6
9%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.2
2%
3.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
MY
Y
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
Average EV/EBIT: 1 697.6
5.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.6
14%
1
CH
Roche Holding AG
SIX:ROG
11.1
6%
1.8
CH
Novartis AG
SIX:NOVN
13.1
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
196.5
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10.5
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
10%
1

See Also

Summary
YSPSAH intrinsic value, competitors valuation, and company profile.
DCF Valuation
YSPSAH stock valuation using Discount Cash Flow valuation method.
Relative Valuation
YSPSAH stock valuation using valuation multiples.
Wall Street Estimates
YSPSAH price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
YSPSAH stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 254,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.